{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:19:40Z","timestamp":1790630380659,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.urolonc.2026.111091","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:31:17Z","timestamp":1775712677000},"page":"119-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"44","author":[{"given":"Yu Guang","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khi Yung","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Abern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7806-9569","authenticated-orcid":false,"given":"Benjamin Jia Han","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey JJ","family":"Leow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung Wen","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae Jack","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John SP","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason YS","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy YC","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2026.111091_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.111091_bib0002","series-title":"EAU guidelines on non-muscle-invasive bladder cancer (T1, T1 and CIS)","author":"Gontero","year":"2023"},{"key":"10.1016\/j.urolonc.2026.111091_bib0003","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.eururo.2012.04.052","article-title":"Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma","volume":"65","author":"Xylinas","year":"2014","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111091_bib0004","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.eursup.2006.04.008","article-title":"Improving patient outcomes: optimal BCG treatment regimen to prevent progression in superficial bladder cancer","volume":"5","author":"Lamm","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111091_bib0005","first-page":"440","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscleinvasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111091_bib0006","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette\u2013Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111091_bib0007","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjc.6690643","article-title":"Cytogenetic monoclonality in multifocal uroepithelial carcinomas: evidence of intraluminal tumour seeding","volume":"81","author":"Fadl-Elmula","year":"1999","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111091_bib0008","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111091_bib0009","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/bju.15344","article-title":"Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer","volume":"128","author":"Bree","year":"2021","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111091_bib0010","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000524449","article-title":"Patients with non-muscle-invasive bladder cancer previously treated with nephroureterectomy have a high risk of recurrence after Bacillus Calmette\u2013Gu\u00e9rin Intravesical Instillation therapy","volume":"68","author":"Maeyama","year":"2023","journal-title":"Chemotherapy"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111091_bib0011","doi-asserted-by":"crossref","first-page":"289.e7","DOI":"10.1016\/j.urolonc.2024.05.007","article-title":"Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma","volume":"42","author":"Massari","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111091_bib0012","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2026.111091_bib0013","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111091_bib0014","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1191\/1740774505cn087oa","article-title":"Meta-analysis of individual patient data from randomized trials: a review of methods used in practice","volume":"2","author":"Simmonds","year":"2005","journal-title":"Clinical Trials"},{"key":"10.1016\/j.urolonc.2026.111091_bib0015","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"issue":"0","key":"10.1016\/j.urolonc.2026.111091_bib0016","article-title":"Subcutaneous versus transvenous implantable defibrillator therapy: a systematic review and meta-analysis of randomized trials and propensity score\u2013Matched studies","volume":"0","author":"Fong","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111091_bib0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111091_bib0018","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"7414","key":"10.1016\/j.urolonc.2026.111091_bib0019","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111091_bib0020","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/jjco\/hyac068","article-title":"Significant impact of a history of prior or concomitant upper urinary tract cancer on the recurrence and progression of non-muscle invasive bladder cancer","volume":"52","author":"Matsushita","year":"2022","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111091_bib0021","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bju.14111","article-title":"Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Gu\u00e9rin after radical nephroureterectomy for upper urinary tract urothelial carcinoma","volume":"121","author":"Miyake","year":"2018","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111091_bib0022","doi-asserted-by":"crossref","first-page":"S1078","DOI":"10.1016\/j.urolonc.2025.03.026","article-title":"BCG response and oncological outcomes in high risk non-muscle invasive bladder cancer following previously treated upper tract urothelial carcinoma: a propensity-matched analysis","volume":"43","author":"Lim","year":"2025","journal-title":"Urologic Oncolog"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111091_bib0023","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.21037\/tau.2019.11.22","article-title":"Epidemiology, clinical presentation, and evaluation of upper-tract urothelial carcinoma","volume":"9","author":"Petros","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.111091_bib0024","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cam4.3007","article-title":"Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): a cohort analysis","volume":"9","author":"Jobczyk","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2026.111091_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1170124","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Grabe-Heyne","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111091_bib0026","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1038\/s41598-025-89525-9","article-title":"Impact of upper tract urothelial carcinoma history on patients with non-muscle invasive bladder cancer undergoing intravesical chemotherapy","volume":"15","author":"Ji","year":"2025","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111091_bib0027","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/BLC-150015","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) treatment failures in non-muscle invasive bladder cancer: what truly constitutes unresponsive disease","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111091_bib0028","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/MOU.0000000000000769","article-title":"Bladder-preserving strategies for Bacillus Calmette\u2013Gu\u00e9rin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?","volume":"30","author":"Sari Motlagh","year":"2020","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2026.111091_bib0029","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00345-012-0946-6","article-title":"Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours","volume":"31","author":"Yates","year":"2013","journal-title":"World J Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.111091_bib0030","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1056\/NEJM199203123261108","article-title":"Bladder cancer-field versus clonal origin","volume":"326","author":"Harris","year":"1992","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111091_bib0031","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2013.09.003","article-title":"Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool","volume":"65","author":"Xylinas","year":"2014","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111091_bib0032","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1442-2042.2005.01155.x","article-title":"Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications","volume":"12","author":"Habuchi","year":"2005","journal-title":"Int J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111091_bib0033","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.eururo.2014.11.035","article-title":"A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma","volume":"67","author":"Seisen","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111091_bib0034","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bju.13935","article-title":"Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis","volume":"120","author":"Marchioni","year":"2017","journal-title":"BJU Int"},{"issue":"54","key":"10.1016\/j.urolonc.2026.111091_bib0035","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1038\/sj.onc.1206964","article-title":"Distinct patterns of microsatellite instability are seen in tumours of the urinary tract","volume":"22","author":"Catto","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2026.111091_bib0036","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.euo.2020.12.007","article-title":"Genetic differences between bladder and upper urinary tract carcinoma: implications on therapy","volume":"4","author":"Sfakianos","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"697","key":"10.1016\/j.urolonc.2026.111091_bib0037","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn4118","article-title":"Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin","volume":"15","author":"de Jong","year":"2023","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111091_bib0038","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/jcm13051305","article-title":"FGFR3 mutations in urothelial carcinoma: a single-center study using next-generation sequencing","volume":"13","author":"Yu","year":"2024","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111091_bib0039","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.3390\/ijms24021776","article-title":"Genetic interference of FGFR3 impedes invasion of upper tract urothelial carcinoma cells by alleviating RAS\/MAPK signal activity","volume":"24","author":"Huang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111091_bib0040","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111091_bib0041","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.18632\/aging.203980","article-title":"TP53\/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types","volume":"14","author":"Cao","year":"2022","journal-title":"Aging"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111091_bib0042","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"16","key":"10.1016\/j.urolonc.2026.111091_bib0043","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive Bladder Cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111091_bib0044","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.euo.2024.06.005","article-title":"The role of mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"7","author":"Scilipoti","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600102X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600102X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:28:43Z","timestamp":1778200123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392600102X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S107814392600102X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111091","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}